Last reviewed · How we verify
Humoral hypercalcemia of malignancy
Approved treatments
- Didronel · Procter And Gamble
- Solu-Cortef · Pfizer
- Bisphonal · Astellas Pharma
- Cortifoam · Pfizer
- Cortone
- Celestone Soluspan
- Decadron · Generic (originally Merck)
- Neridronate
Neridronate works by inhibiting the enzyme Farnesyl pyrophosphate synthase, which plays a crucial role in bone resorption. - Ethidronate · Centre National d'Etudes Spatiales
- pamidronate · US Department of Veterans Affairs
- prednison · Wen Zhang
- Medrol · Generic (originally Upjohn/Pfizer)
Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions. - Cortef · Generic (originally Merck/Upjohn)
- Aredia
- Rodinolone
- Deltasone · Generic (originally Schering)
- Depo-Medrol · Pfizer
Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response. - Zometa · Novartis
Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity. - Betametasone
Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system. - Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- Zometa · University of Arkansas
- Neridronate · Ente Ospedaliero Ospedali Galliera
- prednisolon · Hannover Medical School
- Methylprednisolon · Leiden University Medical Center
- Zoledronate · Children's Hospital Medical Center, Cincinnati
- Etidronate · Organon and Co
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Humoral hypercalcemia of malignancy patent landscape — cliff calendar, originator estates, attackable patents
- Humoral hypercalcemia of malignancy treatment landscape brief
- Humoral hypercalcemia of malignancy treatment updates RSS
Frequently asked questions about Humoral hypercalcemia of malignancy
What drugs treat Humoral hypercalcemia of malignancy?
Tracked treatments include Didronel, Solu-Cortef, Bisphonal, Cortifoam, Cortone, Celestone Soluspan, Decadron, Neridronate.
What is the treatment for Humoral hypercalcemia of malignancy?
Standard treatment for Humoral hypercalcemia of malignancy includes Didronel, Solu-Cortef, Bisphonal, Cortifoam, Cortone. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Humoral hypercalcemia of malignancy patent cliff · Humoral hypercalcemia of malignancy CI report
- Treatment: Didronel · Procter And Gamble
- Treatment: Solu-Cortef · Pfizer
- Treatment: Bisphonal · Astellas Pharma
- Treatment: Cortifoam · Pfizer
- Treatment: Cortone
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing